Retroscreen Virology Group, which creates drugs and vaccines for a number of viral respiratory diseases, has signed a Viral Challenge Model contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study.
The contract, valued at £5.9m, will be the largest RSV challenge study conducted by Retroscreen to-date.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Will “Liberation Day” strike again?Donald Trump’s 90-day tariff pause comes to an end on 9 July. Can we expect further market turmoil?
-
Israel claims victory in the '12-day war' with IranDonald Trump may have announced a ceasefire in the 12-day war between Israel and Iran, but what comes next depends on what happens internally in Iran
